All Releases
 |
Analysis of Data from Two Phase 3 Studies Shows DIFICID® Offered Faster Diarrheal Symptom Improvement than Oral Vancomycin in Patients with Cancer Being Treated for Clostridium difficile-Associated Diarrhea (CDAD)
May 16, 2012
|
16.1 KB |
| |
SAN DIEGO, May 16, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the results of a retrospective subpopulation analysis of 183 patients with cancer from the company's two large Phase 3 trials, which showed the cancer patients with Clostridium difficile-associated diarrhea (CDAD) who were treated with DIFICID®...
|
|
Optimer Pharmaceuticals Reports First Quarter 2012 Financial Results
May 10, 2012
|
22.9 KB |
| |
SAN DIEGO, May 10, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the Company's financial results for the quarter ended March 31, 2011.
(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)
First Quarter 2012 Financial Highlights
DIFICID® first quarter net sales increas...
|
|
Optimer Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
May 3, 2012
|
8.7 KB |
| |
SAN DIEGO, May 3, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the Bank of America Merrill Lynch 2012 Health Care Conference on Thursday, May 17 at 10:00 AM Pacific Time in Las Vegas, NV.
(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)
A live audio we...
|
|
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 1, 2012
|
8.8 KB |
| |
SAN DIEGO, May 1, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on April 30, 2012 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 17,000 shares of common stock to 6 employees.
(Logo: http://photos.prnewswire.com/prnh/20090...
|
|
Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2012 Financial Results
Apr 25, 2012
|
9.4 KB |
| |
In the news release, Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2012 Financial Results, issued 25-Apr-2012 by Optimer Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that Optimer will report first quarter 2012 financial results after the NASDAQ Global Market closes on May 10, rather th...
|
|
Optimer Pharmaceuticals Announces Personnel Changes
Apr 9, 2012
|
14.2 KB |
| |
SAN DIEGO, April 9, 2012 /PRNewswire/ -- Optimer Pharmaceuticals (NASDAQ: OPTR) ("the Company" or "Optimer") today announced its Board of Directors has appointed Hank McKinnell as its new Chairman. Dr. McKinnell was previously appointed Lead Independent Director at the February 29, 2012 Board meeting. The Company also announced that Kurt Hartman &m...
|
|
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 2, 2012
|
9.0 KB |
| |
SAN DIEGO, April 2, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on March 30, 2012 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 27,000 shares of common stock to 7 new employees.
(Logo: http://photos.prnewswire.com/prn...
|
|
Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult Cancer Patients Being Treated for Clostridium difficile-Associated Diarrhea (CDAD)
Mar 30, 2012
|
15.1 KB |
| |
SAN DIEGO, March 30, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced the presentation of results from a post-hoc subgroup analysis of the company's two large Phase 3 trials which demonstrated that cancer patients with Clostridium difficile-associated diarrhea (CDAD) had higher clinical cure rates, better sustained respon...
|
|
Optimer Pharmaceuticals, Inc. and Astellas Pharma Inc. Enter Collaboration to Commercialize Fidaxomicin for Clostridium difficile Infection in Japan
Mar 29, 2012
|
14.7 KB |
| |
SAN DIEGO and TOKYO, March 29, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) and Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) announced today the execution of an exclusive collaboration and license agreement to develop and commercialize fidaxomicin tablets in Japan for the treatment of Clostridium difficile Infection (CDI).
...
|
|
Optimer Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference
Mar 28, 2012
|
9.5 KB |
| |
SAN DIEGO, March 28, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the 11th Annual Needham Healthcare Conference on Tuesday, April 3 at 3:20 p.m. Eastern Time in New York, NY.
(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)
A live audio webcast of the...
|
|
The Lancet Infectious Diseases Publishes Phase 3 Study Results Confirming Superior Rate of Sustained Clinical Response of DIFICID® (fidaxomicin) Tablets Compared to Oral Vancomycin in Adult Patients with Clostridium difficile Infection (CDI)
Mar 26, 2012
|
15.0 KB |
| |
SAN DIEGO, March 26, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today The Lancet Infectious Diseases has published results from the European and North American Phase 3 trial evaluating the safety and efficacy of DIFICID® (fidaxomicin) tablets in the treatment of adult patients with Clostridium difficile infecti...
|
|
Optimer Reports Fourth Quarter and Fiscal Year 2011 Financial Results
Mar 7, 2012
|
22.6 KB |
| |
SAN DIEGO, March 7, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today financial results for the fourth quarter and fiscal year ended December 31, 2011, and provided an update on the DIFICID® (fidaxomicin) launch for the first two months of 2012.
2011 Financial Highlights
Total revenues in 2011 were $145 mi...
|
|
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 2, 2012
|
9.0 KB |
| |
SAN DIEGO, March 2, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on February 29, 2012 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 52,375 shares of common stock to 9 new employees.
(Logo: http://photos.prnewswire.com/p...
|
|
Optimer Pharmaceuticals to Present at the 32nd Annual Cowen Health Care Conference
Feb 27, 2012
|
9.6 KB |
| |
SAN DIEGO, Feb. 27, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the 32nd Annual Cowen Health Care Conference on Wednesday, March 7 at 8:40 AM Eastern Time in Boston, MA.
(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO )
A live audio webcast of the pr...
|
|
Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and FY 2011 Financial Results
Feb 27, 2012
|
9.8 KB |
| |
SAN DIEGO, Feb. 27, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) will report fourth quarter 2011 and fiscal year 2011 financial results and provide a business overview, including DIFICID® sales, commercialization and development, after the NASDAQ Global Market closes on March 7th. The Company will host a conference call t...
|
|
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 1, 2012
|
9.1 KB |
| |
SAN DIEGO, Feb. 1, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on January 31, 2012 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 167,875 shares of common stock to 13 new employees.
(Logo: http://photos.prnewswire.com/p...
|
|
Chief Operating Officer Tessie M. Che Departing Company
Jan 12, 2012
|
11.0 KB |
| |
SAN DIEGO, Jan. 12, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that Tessie M. Che, Ph.D., Chief Operating Officer & Senior Vice President, Corporate Affairs, is departing the Company to pursue other interests.
(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)
"For the past decade, ...
|
|
Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) Tablets Launch
Jan 9, 2012
|
14.6 KB |
| |
SAN DIEGO, Jan. 9, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today provided an update on commercial sales of DIFICID® (fidaxomicin) tablets since launching the antibacterial drug in July 2011 for the treatment of Clostridium difficile associated-diarrhea (CDAD) in adults 18 years of age or older in the United States.
...
|
|
Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Jan 3, 2012
|
9.0 KB |
| |
SAN DIEGO, Jan. 3, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the 30th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10 at 8:30 AM Pacific Time.
(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO )
A live audio webcast of the presentatio...
|
|
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 3, 2012
|
9.1 KB |
| |
SAN DIEGO, Jan. 3, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on December 22, 2011 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 39,625 shares of common stock to 4 new employees.
(Logo: http://photos.prnewswire.com/pr...
|
|
|
